Komal Jhaveri, MD, FACP

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.

An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.

Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.

Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.

Strategies used to help monitor and manage T-DXd treatment-related adverse events.

Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.